Article produced in association with Jeen Health
On 24 January 2026, NHS England launched the NHS National Inherited Cancer Predisposition Register – a programme that will eventually cover around 120 cancer susceptibility genes.
For adults over 50, this matters more than it first appears.
Cancer risk accelerates with age. Diagnoses in later life – breast, ovarian, prostate, bowel, pancreatic – often carry a genetic component that goes unrecognised.
Hereditary cancer testing has historically been reserved for those with obvious family histories or early-onset disease in close relatives. The new register widens that window.
It also surfaces an uncomfortable question for people already in their fifties, sixties and seventies: does testing still matter at my age? For many, it still does.
What the new NHS inherited cancer register actually does
The programme builds a single national record of individuals known to carry faults in cancer susceptibility genes.
For those identified – including people with variants in BRCA1, BRCA2, the Lynch syndrome genes, PALB2 and many others – the register triggers structured invitations to enhanced screening.
This formalises what has until now been inconsistent.
Whether someone identified as high-risk actually received the additional mammograms, MRIs, colonoscopies or prostate checks that evidence supports has depended heavily on local pathways and personal follow-through. A national register creates a consistent pathway for risk-stratified cancer surveillance across the health service.
The gene list is broad. It includes the hereditary breast and ovarian cancer genes (BRCA1, BRCA2, PALB2, CHEK2), the Lynch syndrome genes linked to colorectal and endometrial cancer (MLH1, MSH2, MSH6, PMS2, EPCAM), and a long list of others linked to pancreatic, prostate, melanoma and rarer cancers.
Why inherited cancer risk still matters after 50
A common belief is that genetic testing for cancer is something you do in your thirties or not at all. The evidence does not support this.
Macmillan Cancer Support sets out the UK figures clearly. Women carrying a BRCA1 variant have a lifetime ovarian cancer risk of 36 to 53 per cent by age 80, against roughly 2 per cent in the general population, and a lifetime breast cancer risk in the region of 70 per cent, against a 14 per cent general-population risk.
Women already treated for one BRCA-related breast cancer carry a substantially elevated risk of a second primary.
For men, BRCA2 variants are linked to an approximately two-fold increase in lifetime prostate cancer risk and to more aggressive disease patterns.
None of these risks disappear after menopause or after 60. In several cases – pancreatic cancer, prostate cancer, second primary breast cancers – the risk in fact peaks in later life.
Identifying a pathogenic variant at 55 or 65 still changes management.
It influences screening frequency, the threshold for investigating new symptoms, and the treatment options that become available.
PARP inhibitors such as olaparib and niraparib have meaningfully improved outcomes for people with BRCA-related breast, ovarian and prostate cancers – but they are only an option when the variant is known.
Who the register will reach – and who it will miss
The NHS register works well for those already flagged through standard referral criteria: strong family history, Ashkenazi Jewish ancestry, early-onset disease, or rare cancer patterns across relatives.
These pathways are defined in NICE guideline CG164 on familial breast cancer and in equivalent Lynch syndrome and hereditary polyposis pathways.
It works less well for people who do not meet those thresholds but carry variants anyway.
A meaningful share of BRCA carriers do not present the classical family history pattern that triggers NHS testing.
Family trees get smaller with fewer children per generation; information about grandparents’ or great-aunts’ cancers is often lost.
Adoptees and those with limited family contact may have no accessible history at all. For these groups, NHS eligibility for hereditary cancer testing can be a closed door even when genuine risk exists.
For this group, a private multi-gene panel – delivered through a registered genetic counsellor service such as that provided by Jeen Health – is typically the most direct route to the same clinical information, with the result feeding into the same NHS surveillance pathway once a pathogenic variant is identified.
Private genetic testing for cancer: what it covers and when it fits
Private genetic testing for cancer has expanded substantially across the UK over the last three years.
Expanded panels now typically cover between 30 and 80 or more cancer susceptibility genes from a single saliva or blood sample, rather than BRCA1 and BRCA2 alone.
For older adults, three scenarios tend to drive the decision:
- Family history exists, but the pattern does not meet NHS eligibility thresholds.
- A relative has been diagnosed, but their result will not arrive in time to influence your own screening decisions.
- You have already had one cancer and want to quantify the risk of a second primary.
Pricing for a multi-gene panel with genetic counsellor involvement typically sits between £500 and £1,200, depending on the breadth of the panel and the depth of pre- and post-test counselling included.
A minimum standard worth insisting on is that the analysis is performed in a UKAS-accredited laboratory and that results are delivered with access to a registered genetic counsellor – not a GP interpreting a PDF.
What a positive result means in later life
A pathogenic variant result is not a diagnosis. It is a risk modifier.
What happens next depends on the gene, the cancer type, your age, and what has already happened in your own medical history.
For BRCA carriers in their fifties or sixties, options generally include enhanced breast MRI and mammography for women, discussion of risk-reducing oophorectomy if not already performed, structured prostate surveillance including PSA and MRI for men, and – where applicable – review of Lynch syndrome colonoscopy intervals.
NHS specialist genetics teams accept onward referrals from positive private tests, provided the test was performed to clinical standards.
For patients who prefer a test without a queue and a face-to-face review of results, in-person cancer genetic counselling is available through specialist services in London.
The new inherited cancer register is designed to receive these cases into the same national surveillance pathway.
The wider picture
The launch of the NHS National Inherited Cancer Predisposition Register is the most significant structural change in UK hereditary cancer care for a decade.
It does not replace the need for individual decisions about testing, particularly for older adults whose family histories were never fully captured and whose windows for preventive action are shorter than those of younger carriers.
For those who meet NHS criteria, the pathway is clearer than it has ever been. For those who do not, a private cancer risk assessment through an accredited laboratory with registered genetic counsellor support remains the most direct route to getting information in time to act on it.
If you have a family or personal history you would like reviewed, a genetic counsellor consultation is the appropriate first step.
Disclaimer: This article is produced for informational purposes only and does not constitute medical advice, diagnosis or treatment.
Clinical guidance referenced reflects published NHS, NICE and Macmillan Cancer Support standards as at April 2026.
Individual circumstances vary; readers are advised to consult a qualified healthcare professional before acting on any information in this article.
This piece was produced in association with Jeen Health, which provided background clinical information for editorial purposes.
Hyperlinks to external sources are included for reference only and do not represent an endorsement of any product, service or organisation.